The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of weekly cabazitaxel for "unfit" metastatic castration resistant prostate cancer patients progressing after docetaxel treatment: Preliminary toxicity analysis (SOGUG-CABASEM trial).
Miguel Angel Climent Duran
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Begoña Perez-Valderrama
No relevant relationships to disclose
Eva Fernandez Parra
No relevant relationships to disclose
Begoña Mellado
No relevant relationships to disclose
Montserrat Domenech
No relevant relationships to disclose
Ovidio Fernandez Calvo
No relevant relationships to disclose
Urbano Anido
No relevant relationships to disclose
Susana Hernando Polo
No relevant relationships to disclose
Jose Angel Arranz
Consultant or Advisory Role - Sanofi
Cristina Caballero
No relevant relationships to disclose
Maria Ochoa de Olza
No relevant relationships to disclose
Daniel E. Castellano
No relevant relationships to disclose